Lehigh Valley Health Network

LVHN Scholarly Works
Department of Pharmacy

Characterization of Prophylactic Antiemetic
Regimens in Pediatric Patients Receiving
Moderately and Highly Emetogenic
Chemotherapy
Jessica Degiacomo PharmD
Lehigh Valley Health Network, Jessica.Degiacomo@lvhn.org

Kristin M. Held PharmD, BCOP
Lehigh Valley Health Network, Kristin_M.Held@lvhn.org

Follow this and additional works at: http://scholarlyworks.lvhn.org/pharmacy
Part of the Chemicals and Drugs Commons, Hematology Commons, Oncology Commons,
Pediatrics Commons, Pharmacy and Pharmaceutical Sciences Commons, and the Therapeutics
Commons
Published In/Presented At
Degiacomo, J., & Held, K. (2013, December 8-12). Characterization of prophylactic antiemetic regimens in pediatric patients receiving
moderately and highly emetogenic chemotherapy. Poster presented at: The American Society of Health-System Pharmacists Midyear
Clinical Meeting, Orlando, FL.

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Characterization of Prophylactic Antiemetic Regimens in Pediatric Patients
Receiving Moderately and Highly Emetogenic Chemotherapy
Jessica Degiacomo, Pharm.D. and Kristin Held, Pharm.D., BCOP
Lehigh Valley Health Network, Allentown, Pennsylvania

Purpose:
The objective of this study is to characterize the prophylactic antiemetic
regimens used in pediatric hematology/oncology patients receiving
moderately and highly emetogenic chemotherapy (MEC/HEC) and to describe
the modifications to their antiemetic regimens with subsequent courses of
chemotherapy.

Background:
•	Recommendations for prophylactic antiemetics differ between adults and
pediatrics
- American Society of Clinical Oncology (ASCO) recommends a serotonin
(5-HT3) antagonist plus a corticosteroid for pediatric patients receiving
1
MEC or HEC
- Patients with a contraindication to corticosteroids should not use a 52
HT3 antagonist alone due to poor CINV control
- Pediatric Oncology Group of Ontario (POGO) suggests nabilone
or chlorpromazine with a 5-HT3 antagonist in patients with a
2
contraindication to corticosteroids
•T
 hese agents are commonly reserved for patients with
2-4
breakthrough CINV due to undesirable side effects
• Recommendation supports the need to add an agent with a
different mechanism of action to replace the corticosteroid within
2-4
the antiemetic regimen

•	Pediatric-specific recommendations are lacking for incorporation of newer
agents into prophylactic antiemetic regimens
• Breakthrough emesis is a significant problem
- More than 90% of patients receiving HEC will have emesis and
5
prophylactic antiemetics will only reduce vomiting to about 30%
- Prophylactic regimens should be modified and tailored to the individual
patient to prevent CINV with subsequent chemotherapy cycles
- No studies have shown one agent or strategy to be superior

Study Design:
•	Retrospective medical record review
•	Inclusion criteria:
- Patients less than 18 years of age at time of first MEC or HEC course
between July 1, 2008 to June 30, 2013
- Receipt of first MEC or HEC course for an oncologic diagnosis during
an inpatient admission to a pediatric service
- Patients must have received at least one subsequent course of
MEC or HEC during an inpatient admission to pediatric hematology/
oncology service to be evaluated for modification of antiemetic
regimen

•	Exclusion criteria:
- Patients 18 years of age and older at time of first MEC or HEC course
- Outpatient chemotherapy administrations
- Patients with documented nausea and/or vomiting related to cause
other than chemotherapy
- Patients who received radiation therapy prior to initiation of
chemotherapy

•	The primary outcomes of this study will be to describe the combinations
of antiemetic regimens that patients received following receipt of MEC or
HEC and to report the percentage of patients whose prophylactic antiemetic
regimens were modified for subsequent courses of chemotherapy

Methods:
•	Pediatric hematology/oncology admission records will be used to generate a
list of patients
5
•	Emetogenicity will be classified as reported by the NCCN guidelines
• Patient data to be collected will include:
- Age, gender, body weight, body surface area
- Diagnosis
- Chemotherapy regimen (protocol, drug, dose, route), emetogenicity of
regimen
- Antiemetic regimens (initial, modified and breakthrough; drug, dose,
route, frequency, days of administration, number of doses)
- Emetic events
- Antiemetic adverse drug reaction history

•	Following data collection, the percentages of pediatric oncology patients
receiving MEC or HEC who experience breakthrough nausea and/or vomiting
will be calculated. Of those patients, the percentage who had their antiemetic
regimen modified for subsequent courses of chemotherapy will be calculated.
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